Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stem cell technology promises better grafts:

This article was originally published in Clinica

Executive Summary

The US company Progenitor has received a patent for its technology for processing blood stem cells capable of developing into blood or blood vessel cells. These could be used in bone marrow transplantation, vascular grafts, coatings and other therapeutic applications. The Menlo Park, California-based firm grows stem cells from the yolk sac, a tissue that appears very briefly in the early development of mammals.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts